CareDx Inc. announced new data to be presented at the 2024 American Transplant Congress (ATC) being held June 1-5 in Philadelphia. CareDx solutions are featured in 36 oral presentations and posters, and a symposium. Key data to be presented at 2024 ATC: Utilization of Artificial Intelligence (AI) in Predicting the Risk of Kidney Allograft Rejection, S. V.ah, S. V. Shah, S. Voora, P. J. Hanson, et al.oster Abstract Session C062.

The study reveals that patients developing cancer after heart transplantation have lower mean levels of both AlloMap®? gene-expression profiling and AlloSure dd-cfDNA before cancer diagnosis compared to propensity-matched patients. A leading group of experts in the field will present findings from the recent SHORE (Surve surveillance HeartCare Outcomes Registry) publication and the latest data featuring AlloSure Kidney and AlloView, the first AI-derived model to predict rejection risk in kidney transplant patients.

Panelists include Alexandre Loupy, MD, PhD, Paris Transplant Group, Darshana Dadhania, MD, Weill-Cornell Medicine, Gaurav Gupta, MD, Virginia Commonwealth University, and Sean Pinney, MD, Mount Sinai Morningside.